Month: May 2025

Preclinical Study from Children’s Hospital of Philadelphia Highlights Innovative Approach to Replacing Brain Cells in the Treatment of Leukodystrophies

05/09/2025

Research shows potential for brain-specific replacement over Hematopoietic Stem Cell Transplantation, which impacts the entire immune system Excerpt from the Press Release: PHILADELPHIA, April 30, 2025 /PRNewswire/ — Researchers at Children’s Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania announced the first ever direct approach to the depletion and…

Read More

Biosplice Announces First Patient Dosed in Phase 2 Trial of Cirtuvivint for Advanced Soft-Tissue Sarcomas

05/08/2025

Multicenter study sponsored by SELNET to evaluate cirtuvivint as a second-line monotherapy in selected sarcoma subtypes Excerpt from the Press Release: SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) — Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small molecule inhibition of CDC-like kinases (CLK) and Dual-specificity tyrosine phosphorylation-regulated (DYRK) kinases, today announced…

Read More

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

05/07/2025

Excerpt from the Press Release: BOSTON, May 1, 2025 /PRNewswire/ — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced further progress in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer. TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit…

Read More

Join The TrialStat Team in Bethesda, Maryland at the Clinical Outsourcing Group DMV Meeting!

05/06/2025

TrialStat will be showcasing our cutting-edge EDC Platform with integrated Medical Imaging Workflow Platform at the COG DMV meeting in Bethesda, Maryland on May 13th – 14th. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing clinical research and streamlining clinical trial execution for Sponsors and CROs. Meet with…

Read More

New Study Reports Reduction in Rehospitalization After Lung Transplantation Utilizing Paragonix Preservation Devices

05/06/2025

Findings from the GUARDIAN-Lung Registry highlight statistically significant reductions in hospital readmissions and acute rejection rates with advanced hypothermic lung preservation technologies Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–Paragonix Technologies, a leader in organ transplant technologies and organ procurement services, announced new lung preservation research at the 45th ISHLT Annual Meeting and Scientific Sessions.…

Read More

Element Science Receives FDA Approval for the Revolutionary Jewel® Patch Wearable Cardioverter Defibrillator

05/05/2025

Groundbreaking device sets new standard in the management of patients with an elevated risk of sudden cardiac arrest Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–In a significant leap forward in the care of patients with cardiac disease, Element Science is proud to announce that its innovative Jewel® Patch Wearable Cardioverter Defibrillator (Patch-WCD) has received…

Read More

New England Journal of Medicine Publishes Phase III Data Showing Single-Dose Xofluza Significantly Reduces Influenza Virus Transmission

05/02/2025

Excerpt from the Press Release: South San Francisco, CA — April 24, 2025 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the New England Journal of Medicine (NEJM) has published a detailed analysis of the Phase III CENTERSTONE trial of Xofluza® (baloxavir marboxil).The trial met its primary endpoint,…

Read More

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

05/01/2025

Excerpt from the Press Release: PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, confirms the sustained complete resolution of the lung metastasis, first reported in February 2025, two months…

Read More